STOCK TITAN

Twist Bioscience Corporation (TWST) Stock News

TWST NASDAQ

Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.

Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.

Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) announced fourth-quarter and full-year fiscal 2026 financial results for the periods ended September 30, 2026. The detailed earnings report and investor presentation are available on its Investor Relations Events and Presentations page.

The company plans a conference call and live audio webcast at 8:00 a.m. Eastern Time on November 12, 2026 to discuss the results and provide a business update. A webcast replay will be available for two weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.83%
Tags
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) announced plans to grant 17,681 restricted stock units as employment inducements to recently hired individuals.

The awards cover 19 new hires under its Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Restricted stock units are equity awards that vest subject to specified conditions. Vesting spans 48 months: some awards vest 25% after one year and quarterly thereafter, while others vest quarterly from the outset. Vesting requires continued service through each applicable vesting date. Smaller grants follow semiannual or annual schedules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Adam Laponis will participate in upcoming investor-conference fireside chats.

The Jefferies Global Healthcare Conference chat in London is scheduled for November 17 at 3:00 pm Greenwich Mean Time. The 9th Annual Evercore Healthcare Conference chat in Coral Gables, Florida, is scheduled for December 1 at 7:30 am Eastern Time. Both will be webcast live through the company's Investor Calendar, with replays archived for 30 days after the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.05%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (TWST) launched Twist MRD Express, custom panels for cancer researchers with manufacturing turnaround time starting within one day.

The panels support research into molecular residual disease, small amounts of tumor-derived material remaining after cancer treatment. They can include up to 10,000 probes. Twist says manufacturing and automation enhancements enable personalized, tumor-informed panels on timelines associated with tests using shared cancer biomarkers. Applications include oncology research, biomarker discovery and test development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (TWST) expanded its antibody production and characterization portfolio with the launch of its Express Screening Antibodies offering.

The cell-free workflow produces purified full-length antibodies from customer-defined sequences and offers SPR binding characterization, a method for measuring molecular binding. Twist says turnaround starts at five days, with purified antibody quantities ranging from 5 μg to 20 μg. The offering complements existing workflows by supporting early screening before selected antibodies advance to further production and characterization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
none
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) will report fiscal 2026 fourth-quarter and full-year financial results before the market opens on November 12, 2026.

The results cover the periods ended September 30, 2026. The company plans a conference call and live audio webcast at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Results will be available on its Investor Relations website before the call, and the webcast replay will remain available for two weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
earnings date
-
Rhea-AI Summary

Twist Bioscience (TWST) entered an agreement with Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly, to provide antibody characterization data services that support TuneLab’s antibody prediction models, including AbLab.

Participating companies using TuneLab will be able to order antibody services from Twist via TuneLab’s preferred Twist protocols to generate high-quality wet lab data that can train and refine AI models. This connects Twist’s high-throughput experimental capabilities with Lilly’s AI-enabled discovery ecosystem, aiming to help researchers more efficiently down-select antibody candidates and contribute data back into TuneLab for federated model training.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.60%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (TWST) will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, at 1:25 p.m. Eastern Time in New York City.

The session with CEO Emily M. Leproust, Ph.D., and CFO Adam Laponis will be webcast live via the Investor Calendar page of Twist Bioscience’s investor relations website. A replay of the event will be archived and available for 30 days after the live presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
Rhea-AI Summary

Twist Bioscience (Nasdaq: TWST) priced an upsized underwritten public offering of 3,125,000 common shares at $96.00 per share, for expected gross proceeds of $300.0 million before fees and expenses. The company granted underwriters a 30-day option to purchase up to 468,750 additional shares at the same public price, less underwriting discounts and commissions.

The offering is expected to close on August 6, 2026, subject to customary conditions. According to Twist, net proceeds plus existing cash will fund R&D investments, manufacturing capacity expansion, product offerings, and general corporate purposes. Goldman Sachs, William Blair, Leerink Partners and Guggenheim Securities are joint book-running managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.65%
Tags

FAQ

What is the current stock price of Twist Bioscience (TWST)?

Twist Bioscience (TWST) last closed at $103.32.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately $7.0B.